ICLR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

2.01B

-1.4%

3.324

-3.09%

2.01B

+0.21%

3.241

+1.58%

2.02B

-0.09%

3.309

+1.49%

Estimates Revision

The market is revising Upward the revenue expectations for ICON Public Limited Company (ICLR) for FY2025, with the revenue forecasts being adjusted by 1.17% over the past three months. During the same period, the stock price has changed by 6.36%.

Revenue Estimates for FY2025

Revise Upward

+1.17%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.01%

In Past 3 Month

Stock Price

Go Up

+6.36%

In Past 3 Month

14 Analyst Rating

Wall Street analysts forecast ICLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICLR is 204.92 USD with a low forecast of 172.00 USD and a high forecast of 236.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

5 Hold

0 Sell

Moderate Buy

Current: 184.135

Low

172.00

Averages

204.92

High

236.00

Current: 184.135

Low

172.00

Averages

204.92

High

236.00

BMO Capital

Sean Dodge

Market Perform

initiated

$175

2025-11-12

Reason

BMO Capital

Sean Dodge

Price Target

$175

2025-11-12

initiated

Market Perform

Reason

BMO Capital analyst Sean Dodge initiated coverage of Icon with a Market Perform rating and $175 price target. The firm's analysis suggests the company's cancellations are likely remain elevated for the next few quarters. However, it also indicates the worst is probably now behind Icon, the analyst tells investors in a research note.

Baird

NULL -> Outperform

maintain

$218 -> $220

2025-10-24

Reason

Baird

Price Target

$218 -> $220

2025-10-24

maintain

NULL -> Outperform

Reason

Baird raised the firm's price target on Icon to $220 from $218 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.

UBS

Buy -> Buy

downgrade

$240 -> $220

2025-10-24

Reason

UBS

Price Target

$240 -> $220

2025-10-24

downgrade

Buy -> Buy

Reason

UBS lowered the firm's price target on Icon to $220 from $240 and keeps a Buy rating on the shares.

TD Cowen

Charles Rhyee

Hold

downgrade

$183 -> $172

2025-10-24

Reason

TD Cowen

Charles Rhyee

Price Target

$183 -> $172

2025-10-24

downgrade

Hold

Reason

TD Cowen analyst Charles Rhyee lowered the firm's price target on Icon to $172 from $183 and keeps a Hold rating on the shares. The firm came away from the conference call still concerned on 2026 estimates, with management expecting margin pressure from pass-throughs to continue into 4Q and next year. Margin pressure from pricing is another headwind to 2026 that hasn't been felt yet.

Barclays

Equal Weight

downgrade

$190 -> $185

2025-10-24

Reason

Barclays

Price Target

$190 -> $185

2025-10-24

downgrade

Equal Weight

Reason

Barclays lowered the firm's price target on Icon to $185 from $190 and keeps an Equal Weight rating on the shares. The firm says the company's gross bookings growth give it confidence that its sales growth likely grows low-single-digits next year. However, it has little confidence that Icon's EBITDA will follow.

Leerink

Outperform

NULL

downgrade

$235 -> $220

2025-10-23

Reason

Leerink

Price Target

$235 -> $220

2025-10-23

downgrade

Outperform

NULL

Reason

Leerink lowered the firm's price target on Icon to $220 from $235 and keeps an Outperform rating on the shares. The firm thinks Icon's negative stock reaction is due to worries on pricing/gross margins that are not new, and, in Leerink's opinion, are likely overblown relative to the valuation. The firm remains positive on the risk/reward and thinks the improved gross awards/RFP flow should help re-establish a better growth profile. The quarter did not include any negative surprises and the improved gross bookings wins/book-to-bill was encouraging, Leerink adds.

Valuation Metrics

The current forward P/E ratio for ICON PLC (ICLR.O) is 13.96, compared to its 5-year average forward P/E of 18.18. For a more detailed relative valuation and DCF analysis to assess ICON PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

18.18

Current PE

13.96

Overvalued PE

22.05

Undervalued PE

14.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

13.48

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

16.18

Undervalued EV/EBITDA

10.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.29

Current PS

0.00

Overvalued PS

2.77

Undervalued PS

1.80

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ICLR News & Events

Events Timeline

No data

News

4.0

12-15Yahoo Finance

BofA Securities Changes ICON Rating from Buy to Neutral

6.5

12-09Businesswire

ICON Releases 2025 Global Biotech Survey, 92% Executives Show Strong Confidence

7.5

12-02Businesswire

ICON Reports Clinical Trial Startup Survey, 55% of Respondents Say Activation Time Exceeds 5 Months

People Also Watch

Frequently Asked Questions

What is ICON PLC (ICLR) stock price today?

The current price of ICLR is 184.135 USD — it has decreased -0.13 % in the last trading day.

What is ICON PLC (ICLR)'s business?

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

What is the price predicton of ICLR Stock?

What is ICON PLC (ICLR)'s revenue for the last quarter?

ICON PLC revenue for the last quarter amounts to 2.04B USD, increased 0.63 % YoY.

What is ICON PLC (ICLR)'s earnings per share (EPS) for the last quarter?

ICON PLC. EPS for the last quarter amounts to 0.03 USD, decreased -98.73 % YoY.

What changes have occurred in the market's expectations for ICON PLC (ICLR)'s fundamentals?

How many employees does ICON PLC (ICLR). have?

ICON PLC (ICLR) has 41900 emplpoyees as of December 16 2025.

What is ICON PLC (ICLR) market cap?

Today ICLR has the market capitalization of 14.08B USD.